Belite Bio, Inc Nov 22, 2026 Copy link Belite Bio Announces Extension of FDA Review Timeline for Tinlarebant NDA SAN DIEGO, Nov. 20, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a Business
Belite Bio, Inc Nov 12, 2026 Copy link Belite Bio Reports Unaudited Third Quarter 2026 Financial Results and Provides a Corporate Update New Drug Application (NDA) for tinlarebant in Stargardt disease type 1 (STGD1) granted priority review by the U.S. Business
Belite Bio, Inc Nov 5, 2026 Copy link Belite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial Results SAN DIEGO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a Business
Belite Bio, Inc Oct 19, 2026 Copy link Belite Bio Announces Uplisting to the Nasdaq Global Select Market SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a Business
Belite Bio, Inc Oct 14, 2026 Copy link Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1 If approved, tinlarebant would be the first-ever approved treatment for Stargardt Disease Type 1 in Singapore, United Business
Belite Bio, Inc Oct 1, 2026 Copy link Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a Business
Belite Bio, Inc Sep 28, 2026 Copy link Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a Business
Belite Bio, Inc Sep 8, 2026 Copy link Belite Bio submits tinlarebant NDA in Japan for Stargardt Disease Belite Bio announces NDA submission for tinlarebant to Japan's MHLW for Stargardt disease type 1 under Sakigake designation, aiming for first-in-class treatment. Business
Belite Bio, Inc Sep 1, 2026 Copy link Belite Bio to Participate in Four Upcoming Investor Conferences SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a Business
Belite Bio, Inc Aug 24, 2026 Copy link Belite Bio to Host Virtual Commercial Day on September 2, 2026 SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a Business
Belite Bio, Inc Aug 21, 2026 Copy link Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a Business
Belite Bio, Inc Aug 12, 2026 Copy link Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) with Priority Review for tinlarebant Business